Marinol Related Published Studies
Well-designed clinical trials related to Marinol (Dronabinol)
Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. [2008.03]
Patients with chronic pain on opioid therapy taking dronabinol: incidence of false negatives using radioimmunoassay. [2008.01]
Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. [2007.12.12]
Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. [2007.08.15]
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. [2007.03]
[Effects of oral cannabis and dronabinol on driving capacity] [2006.05]
Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. [2005.08]
[Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary publication] [2005.06.20]
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. [2004.07.31]
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. [2002.01.15]
The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. [1997.03.01]
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. [1995.02]
Effect of dronabinol on nutritional status in HIV infection. [1993.07]
Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. [1990.12]
Well-designed clinical trials possibly related to Marinol (Dronabinol)
Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial. [2008.08.06]
Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. [2008.07]
Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. [2008.04]
Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. [2008.03.05]
Nabilone for the treatment of pain in fibromyalgia. [2008.02]
Excretion of Delta9-tetrahydrocannabinol in sweat. [2008.01.30]
Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. [2008.01.26]
Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. [2007.12.15]
Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. [2007.12]
Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. [2007.11]
Vaporization as a smokeless cannabis delivery system: a pilot study. [2007.11]
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. [2007.11]
Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. [2007.10]
Oromucosal Delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. [2007.09]
Cannabinoid concentrations in hair from documented cannabis users. [2007.07.04]
Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. [2007.05]
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. [2007.03]
Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. [2007.02.13]
The effects of low doses of delta-9 tetrahydrocannabinol on reinforcement processing in the risky decision-making of young healthy adults. [2007.02]
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. [2007.01]
An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. [2006.12]
Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. [2006.11.08]
High-potency marijuana impairs executive function and inhibitory motor control. [2006.10]
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. [2006.10]
Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. [2006.09]
Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. [2006.08]
Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. [2006.08]
Effects of nabilone, a synthetic cannabinoid, on postoperative pain. [2006.08]
Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. [2006.07.20]
[Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain--a randomized controlled trial] [2006.06]
Cannabinoids in medicine: A review of their therapeutic potential. [2006.04.21]
Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? [2006.04]
[(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain.] [2006.04]
Low doses of delta-9 tetrahydrocannabinol (THC) have divergent effects on short-term spatial memory in young, healthy adults. [2006.02]
[(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain.] [2006.01.03]
Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. [2006.01]
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. [2005.09.27]
Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. [2005.09]
Transdermal nicotine alters some of marihuana's effects in male and female volunteers. [2005.08.01]
Determination of ajulemic acid and its glucuronide in human plasma by gas chromatography-mass spectrometry. [2005.06.05]
Cannabinoid influence on cytokine profile in multiple sclerosis. [2005.06]
The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. [2005.06]
Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. [2005.03.15]
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. [2004.12]
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. [2004.08]
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. [2004.08]
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. [2004.08]
Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. [2004.05]
Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. [2004.05]
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. [2003.11.08]
Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. [2003.11]
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. [2003.10.01]
The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. [2003.09]
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. [2003.08.19]
Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. [2003.07]
Effects of THC on behavioral measures of impulsivity in humans. [2003.07]
Behavioral and subjective effects of marijuana following partial sleep deprivation. [2003.06.05]
Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. [2003.05]
Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. [2003.04]
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. [2003.02]
Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. [2003.02]
Interaction between naltrexone and oral THC in heavy marijuana smokers. [2003.02]
Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. [2002.11]
The acute effects of tetrahydrocannabinol on auditory threshold and frequency resolution in human subjects. [2002.06]
Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. [2002.06]
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. [2002.05.14]
The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. [2002.03.08]
Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. [2002.03]
Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. [2002.03]
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. [2002.01]
Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. [2002.01]
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. [2001.12.11]
Ethanol increases plasma Delta(9)-tetrahydrocannabinol (THC) levels and subjective effects after marihuana smoking in human volunteers. [2001.10.01]
Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. [2001.04]
Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. [2001.01]
Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. [2000.06.01]
Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans. [2000.06.01]
Effect of cannabis use on cognitive functions and driving ability. [1999.06]
Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. [1999.01]
Laboratory validation study of drug evaluation and classification program: alprazolam, d-amphetamine, codeine, and marijuana. [1998.10]
The effects of tetrahydrocannabinol on the recognition of emotionally charged words: an analysis using event-related brain potentials. [1998]
Comparative effects of alcohol and marijuana on mood, memory, and performance. [1997.09]
Marijuana intoxication and brain activation in marijuana smokers. [1997]
Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana. [1996.10]
Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. [1995.12.01]
Electroencephalographic correlates of marihuana-induced euphoria. [1995.02]
Cannabinoids and appetite stimulation. [1994.09]
|
